<DOC>
	<DOC>NCT01810783</DOC>
	<brief_summary>To determine the safety and efficacy of brexpiprazole during long-term treatment.</brief_summary>
	<brief_title>Brexpiprazole in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>The patient has completed the leadin study 14644A. The patient is judged to potentially benefit from 52week treatment with brexpiprazole according to the clinical opinion of the investigator. The patient agrees to protocoldefined use of effective contraception. The patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during Study 14644A. The patient has a clinically significant unstable illness diagnosed during Study 14644A. The patient, in the opinion of the investigator or according to ColumbiaSuicide Severity Rating Scale (CSSRS), is at significant risk of suicide. The patient has an abnormal ECG or other abnormal ECG tests that are, in the investigator's opinion, clinically significant. The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason. Other inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>